title: Who foots the bill? HMOs confront the rising popularity of designer drugs.
authors: R
authors: R
authors: Shinkman
mesh_terms: D002204:Capitation Fee; D003669:Deductibles and Coinsurance; D011307:Drug Prescriptions / Q000191:economics*; D017049:Employer Health Costs; D004791:Enzyme Inhibitors / Q000191:economics; D006279:Health Maintenance Organizations / Q000191:economics*; D006801:Humans; D019458:Insurance Coverage; D008297:Male; D010879:Piperazines / Q000191:economics; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014481:United States
chemical_list: D004791:Enzyme Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate